28282033|t|PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment
28282033|a|Phosphoinositide-3-kinase and protein kinase B (PI3K - AKT) is upregulated in multiple myeloma (MM). Using a combination of short hairpin RNA (shRNA) lentivirus -mediated knockdown and pharmacologic isoform- specific inhibition we investigated the role of the PI3K p110γ (PI3Kγ) subunit in regulating MM proliferation and bone marrow microenvironment - induced MM interactions. We compared this with inhibition of the PI3K p110δ (PI3kδ) subunit and with combined PI3kδ / γ dual inhibition. We found that MM cell adhesion and migration were PI3Kγ - specific functions, with PI3kδ inhibition having no effect in MM adhesion or migration assays. At concentration of the dual PI3Kδ / γ inhibitor duvelisib, which can be achieved in vivo we saw a decrease in AKT phosphorylation at s473 after tumour activation by bone marrow stromal cells (BMSC) and interleukin-6. Moreover, after drug treatment of BMSC / tumour co-culture activation assays only dual PI3kδ / γ inhibition was able to induce MM apoptosis. shRNA lentiviral -mediated targeting of either PI3Kδ or PI3Kγ alone, or both in combination, increased survival of NSG mice xeno-transplanted with MM cells. Moreover, treatment with duvelisib reduced MM tumour burden in vivo. We report that PI3Kδ and PI3Kγ isoforms have distinct functions in MM and that combined PI3kδ / γ isoform inhibition has anti - MM activity. Here we provide a scientific rationale for trials of dual PI3kδ / γ inhibition in patients with MM.
28282033	0	5	PI3Kδ	T116,T126	C1450115
28282033	10	24	PI3Kγ isoforms	T116,T126	C2713509
28282033	30	38	distinct	T080	C2963144
28282033	39	48	functions	T169	C0542341
28282033	52	62	regulating	T169	C2587213
28282033	63	75	pro-tumoural	T191	C0027651
28282033	76	86	signalling	T043	C0037083
28282033	94	110	multiple myeloma	T191	C0026764
28282033	111	127	microenvironment	T078	C1707328
28282033	128	153	Phosphoinositide-3-kinase	T116,T126	C0044602
28282033	158	174	protein kinase B	T116,T126	C0164786
28282033	176	180	PI3K	T116,T126	C0044602
28282033	183	186	AKT	T116,T126	C0164786
28282033	191	202	upregulated	T044	C0041904
28282033	206	222	multiple myeloma	T191	C0026764
28282033	223	227	(MM)	T191	C0026764
28282033	237	248	combination	T080	C0205195
28282033	252	269	short hairpin RNA	T114	C2930586
28282033	270	277	(shRNA)	T114	C2930586
28282033	278	288	lentivirus	T005	C0079679
28282033	299	308	knockdown	T063	C2350567
28282033	313	344	pharmacologic isoform- specific	T116	C0597298
28282033	336	344	specific	T080	C0205369
28282033	345	355	inhibition	T052	C3463820
28282033	359	371	investigated	T169	C1292732
28282033	376	380	role	T077	C1705810
28282033	388	398	PI3K p110γ	T116,T126	C2713509
28282033	399	406	(PI3Kγ)	T116,T126	C2713509
28282033	407	414	subunit	T116	C0599220
28282033	418	428	regulating	T169	C2587213
28282033	429	431	MM	T191	C0026764
28282033	432	445	proliferation	T043	C0596290
28282033	450	461	bone marrow	T024	C0005953
28282033	462	478	microenvironment	T078	C1707328
28282033	481	488	induced	T169	C0205263
28282033	489	491	MM	T191	C0026764
28282033	492	504	interactions	T169	C1704675
28282033	509	517	compared	T052	C1707455
28282033	528	538	inhibition	T052	C3463820
28282033	546	556	PI3K p110δ	T116,T126	C1450115
28282033	557	564	(PI3kδ)	T116,T126	C1450115
28282033	565	572	subunit	T116	C0599220
28282033	582	590	combined	T080	C0205195
28282033	591	596	PI3kδ	T116,T126	C1450115
28282033	599	600	γ	T116,T126	C2713509
28282033	601	605	dual	T052	C1705764
28282033	606	616	inhibition	T052	C3463820
28282033	632	634	MM	T191	C0026764
28282033	635	648	cell adhesion	T043	C0007577
28282033	653	662	migration	T043	C1622501
28282033	668	673	PI3Kγ	T116,T126	C2713509
28282033	676	684	specific	T080	C0205369
28282033	685	694	functions	T169	C0542341
28282033	701	706	PI3kδ	T116,T126	C1450115
28282033	707	717	inhibition	T052	C3463820
28282033	725	734	no effect	T080	C1301751
28282033	738	740	MM	T191	C0026764
28282033	741	749	adhesion	T043	C0007577
28282033	753	762	migration	T043	C1622501
28282033	763	769	assays	T059	C1510438
28282033	774	787	concentration	T081	C1446561
28282033	795	799	dual	T052	C1705764
28282033	800	805	PI3Kδ	T116,T126	C1450115
28282033	808	809	γ	T116,T126	C2713509
28282033	810	819	inhibitor	T080	C1999216
28282033	820	829	duvelisib	T109,T121	C4079854
28282033	844	852	achieved	T169	C1301820
28282033	853	860	in vivo	T082	C1515655
28282033	870	878	decrease	T081	C0547047
28282033	882	885	AKT	T116,T126	C0164786
28282033	886	901	phosphorylation	T044	C0031715
28282033	905	909	s473	T087	C1519254
28282033	916	922	tumour	T191	C0027651
28282033	923	933	activation	T052	C1879547
28282033	937	962	bone marrow stromal cells	T025	C1640380
28282033	963	969	(BMSC)	T025	C1640380
28282033	974	987	interleukin-6	T116,T129	C0021760
28282033	1005	1019	drug treatment	T061	C0013216
28282033	1023	1027	BMSC	T025	C1640380
28282033	1030	1036	tumour	T191	C0027651
28282033	1037	1047	co-culture	T059	C0430400
28282033	1048	1058	activation	T052	C1879547
28282033	1059	1065	assays	T059	C1510438
28282033	1071	1075	dual	T052	C1705764
28282033	1076	1081	PI3kδ	T116,T126	C1450115
28282033	1084	1085	γ	T116,T126	C2713509
28282033	1086	1096	inhibition	T052	C3463820
28282033	1109	1115	induce	T169	C0205263
28282033	1116	1118	MM	T191	C0026764
28282033	1119	1128	apoptosis	T043	C0162638
28282033	1130	1135	shRNA	T114	C2930586
28282033	1136	1146	lentiviral	T005	C0079679
28282033	1157	1166	targeting	T169	C1521840
28282033	1177	1182	PI3Kδ	T116,T126	C1450115
28282033	1186	1191	PI3Kγ	T116,T126	C2713509
28282033	1210	1221	combination	T080	C0205195
28282033	1223	1232	increased	T081	C0205217
28282033	1233	1241	survival	T052	C0038952
28282033	1245	1253	NSG mice	T015	C0025929
28282033	1254	1271	xeno-transplanted	T122	C0522537
28282033	1277	1279	MM	T191	C0026764
28282033	1280	1285	cells	T025	C0007634
28282033	1297	1306	treatment	T169	C1522326
28282033	1312	1321	duvelisib	T109,T121	C4079854
28282033	1322	1329	reduced	T080	C0392756
28282033	1330	1332	MM	T191	C0026764
28282033	1333	1339	tumour	T191	C0027651
28282033	1340	1346	burden	T078	C2828008
28282033	1347	1354	in vivo	T082	C1515655
28282033	1359	1365	report	T170	C0684224
28282033	1371	1376	PI3Kδ	T116,T126	C1450115
28282033	1381	1395	PI3Kγ isoforms	T116,T126	C2713509
28282033	1401	1409	distinct	T080	C2963144
28282033	1410	1419	functions	T169	C0542341
28282033	1423	1425	MM	T191	C0026764
28282033	1435	1443	combined	T080	C0205195
28282033	1444	1449	PI3kδ	T116,T126	C1450115
28282033	1452	1453	γ	T116,T126	C2713509
28282033	1454	1461	isoform	T116	C0597298
28282033	1462	1472	inhibition	T052	C3463820
28282033	1477	1481	anti	T169	C1555029
28282033	1484	1486	MM	T191	C0026764
28282033	1487	1495	activity	T052	C0441655
28282033	1505	1512	provide	T052	C1999230
28282033	1515	1535	scientific rationale	T170	C0282574
28282033	1540	1546	trials	T062	C0681815
28282033	1550	1554	dual	T052	C1705764
28282033	1555	1560	PI3kδ	T116,T126	C1450115
28282033	1563	1564	γ	T116,T126	C2713509
28282033	1565	1575	inhibition	T052	C3463820
28282033	1579	1587	patients	T101	C0030705
28282033	1593	1595	MM	T191	C0026764